Author
Listed:
- Jun Wang
(Merck Research Laboratories)
- Stephen M. Soisson
(Merck Research Laboratories)
- Katherine Young
(Merck Research Laboratories)
- Wesley Shoop
(Merck Research Laboratories
DuPont Stine-Haskell Research Center
LL Silver Consulting)
- Srinivas Kodali
(Merck Research Laboratories)
- Andrew Galgoci
(Merck Research Laboratories)
- Ronald Painter
(Merck Research Laboratories)
- Gopalakrishnan Parthasarathy
(Merck Research Laboratories)
- Yui S. Tang
(Merck Research Laboratories)
- Richard Cummings
(Merck Research Laboratories)
- Sookhee Ha
(Merck Research Laboratories)
- Karen Dorso
(Merck Research Laboratories)
- Mary Motyl
(Merck Research Laboratories)
- Hiranthi Jayasuriya
(Merck Research Laboratories)
- John Ondeyka
(Merck Research Laboratories)
- Kithsiri Herath
(Merck Research Laboratories)
- Chaowei Zhang
(Merck Research Laboratories)
- Lorraine Hernandez
(Merck Research Laboratories)
- John Allocco
(Merck Research Laboratories)
- Ángela Basilio
(Merck Research Laboratories)
- José R. Tormo
(Merck Research Laboratories)
- Olga Genilloud
(Merck Research Laboratories)
- Francisca Vicente
(Merck Research Laboratories)
- Fernando Pelaez
(Merck Research Laboratories)
- Lawrence Colwell
(Merck Research Laboratories)
- Sang Ho Lee
(Merck Research Laboratories)
- Bruce Michael
(Merck Research Laboratories)
- Thomas Felcetto
(Merck Research Laboratories)
- Charles Gill
(Merck Research Laboratories)
- Lynn L. Silver
(Merck Research Laboratories
DuPont Stine-Haskell Research Center
LL Silver Consulting)
- Jeffery D. Hermes
(Merck Research Laboratories)
- Ken Bartizal
(Merck Research Laboratories)
- John Barrett
(Merck Research Laboratories)
- Dennis Schmatz
(Merck Research Laboratories)
- Joseph W. Becker
(Merck Research Laboratories)
- Doris Cully
(Merck Research Laboratories)
- Sheo B. Singh
(Merck Research Laboratories)
Abstract
New-wave antibiotics The worldwide spread of antibiotic resistance in pathogenic bacteria raises serious concerns that today's front-line antibiotics may become ineffective. So the discovery of a new class of compound with enormous potential as antibiotics is of great interest. Platensimycin is the first member of a novel class of natural products that selectively kills bacteria by inhibiting FabF/FabB proteins, a mechanism of action that is not used by any agents in clinical use. It is a potent antibiotic with broad-spectrum activity against Gram-positive bacteria, including clinically relevant drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. The future of platensimycins is considered in the News pages, and see the antimicrobials Web Focus on http://tinyurl.com/g8omx.
Suggested Citation
Jun Wang & Stephen M. Soisson & Katherine Young & Wesley Shoop & Srinivas Kodali & Andrew Galgoci & Ronald Painter & Gopalakrishnan Parthasarathy & Yui S. Tang & Richard Cummings & Sookhee Ha & Karen , 2006.
"Platensimycin is a selective FabF inhibitor with potent antibiotic properties,"
Nature, Nature, vol. 441(7091), pages 358-361, May.
Handle:
RePEc:nat:nature:v:441:y:2006:i:7091:d:10.1038_nature04784
DOI: 10.1038/nature04784
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Zhijie Yang & Yijun Qiao & Emil Strøbech & Jens Preben Morth & Grit Walther & Tue Sparholt Jørgensen & Kah Yean Lum & Gundela Peschel & Miriam A. Rosenbaum & Viola Previtali & Mads Hartvig Clausen & M, 2024.
"Alligamycin A, an antifungal β-lactone spiroketal macrolide from Streptomyces iranensis,"
Nature Communications, Nature, vol. 15(1), pages 1-12, December.
- Katherine A. Ray & Joshua D. Lutgens & Ramesh Bista & Jie Zhang & Ronak R. Desai & Melissa Hirsch & Takeshi Miyazawa & Antonio Cordova & Adrian T. Keatinge-Clay, 2024.
"Assessing and harnessing updated polyketide synthase modules through combinatorial engineering,"
Nature Communications, Nature, vol. 15(1), pages 1-12, December.
- Clara Lambert & Marine Gaillard & Paprapach Wongdontree & Caroline Bachmann & Antoine Hautcoeur & Karine Gloux & Thomas Guilbert & Celine Méhats & Bastien Prost & Audrey Solgadi & Sonia Abreu & Muriel, 2024.
"The double-edged role of FASII regulator FabT in Streptococcus pyogenes infection,"
Nature Communications, Nature, vol. 15(1), pages 1-14, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:441:y:2006:i:7091:d:10.1038_nature04784. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.